Cargando…

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban

BACKGROUND: Reducing major bleeding events is a challenge when managing anticoagulation in patients with atrial fibrillation. This study evaluated the impact of modifiable and nonmodifiable bleeding risk factors in patients with atrial fibrillation receiving rivaroxaban and estimated the impact of r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kirchhof, Paulus, Haas, Sylvia, Amarenco, Pierre, Hess, Susanne, Lambelet, Marc, van Eickels, Martin, Turpie, Alexander G. G., Camm, A. John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335544/ https://www.ncbi.nlm.nih.gov/pubmed/32079476 http://dx.doi.org/10.1161/JAHA.118.009530

Ejemplares similares

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation
por: Camm, A John, et al.
Publicado: (2014)

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
por: Camm, A. John, et al.
Publicado: (2016)

Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real‐world prospective study
por: Camm, A. John, et al.
Publicado: (2020)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
por: Turpie, Alexander GG
Publicado: (2014)

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
por: Beyer-Westendorf, Jan, et al.
Publicado: (2019)

Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk
por: Haas, Sylvia, et al.
Publicado: (2014)

Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE
por: Ageno, Walter, et al.
Publicado: (2017)

Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and nonvalvular atrial fibrillation
por: Patel, Manesh R., et al.
Publicado: (2018)

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation
por: Fox, Keith A A, et al.
Publicado: (2017)

Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial
por: Hohnloser, Stefan H., et al.
Publicado: (2016)

Impact of anemia on major bleeding in patients taking oral anticoagulants for nonvalvular atrial fibrillation
por: Kinjo, Norito, et al.
Publicado: (2023)

Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation
por: Fox, Keith A A, et al.
Publicado: (2021)

Left atrial appendage closure in atrial fibrillation patients with prior major bleeding or ineligible for oral anticoagulation
por: Wintgens, L. I. S., et al.
Publicado: (2019)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

Challenges of Anticoagulant Therapy in Atrial Fibrillation—Focus on Gastrointestinal Bleeding
por: Scridon, Alina, et al.
Publicado: (2023)

Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban
por: Tamayo, Sally, et al.
Publicado: (2015)

Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation
por: Bassand, Jean-Pierre, et al.
Publicado: (2018)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Impact of Primary Hemostasis Disorders on Late Major Bleeding Events among Anticoagulated Atrial Fibrillation Patients Treated by TAVR
por: Dietrich, Laurent, et al.
Publicado: (2021)

New Cancer Diagnosis After Bleeding in Anticoagulated Patients With Atrial Fibrillation
por: Raposeiras Roubín, Sergio, et al.
Publicado: (2020)

Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients
por: Deitelzweig, Steven, et al.
Publicado: (2021)

Predicting major bleeding among hospitalized patients using oral anticoagulants for atrial fibrillation after discharge
por: Qazi, Jakub Z., et al.
Publicado: (2021)

Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation
por: Souverein, Patrick C., et al.
Publicado: (2020)

A new model to predict major bleeding in patients with atrial fibrillation using warfarin or direct oral anticoagulants
por: Claxton, J’Neka S., et al.
Publicado: (2018)

Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)
por: Rohla, Miklos, et al.
Publicado: (2019)

Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis
por: Sakuma, Ichiro, et al.
Publicado: (2019)

Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism
por: Turpie, Alexander G.G.
Publicado: (2012)

Non–Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence
por: Patti, Giuseppe, et al.
Publicado: (2021)

Major Bleeding Risk in Patients With Non-valvular Atrial Fibrillation Concurrently Taking Direct Oral Anticoagulants and Antidepressants
por: Chang, Kuo-Hsuan, et al.
Publicado: (2022)

Major Bleeding Risk in Atrial Fibrillation Patients Co-Medicated With Non-Vitamin K Oral Anticoagulants and Antipsychotics
por: Chen, Chiung-Mei, et al.
Publicado: (2022)

Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding
por: Lip, Gregory Y. H., et al.
Publicado: (2021)

Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants
por: Ording, Anne Gulbech, et al.
Publicado: (2021)

Concomitant Use of Diltiazem With Direct Oral Anticoagulants and Bleeding Risk in Atrial Fibrillation
por: Xu, Yunwen, et al.
Publicado: (2022)

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
por: Tepper, Ping G., et al.
Publicado: (2018)

Performance of the ABC-bleeding risk score for assessing major bleeding risk in Chinese patients with atrial fibrillation on oral anticoagulation therapy: A real-world study
por: Wang, Yu-Feng, et al.
Publicado: (2022)

Association of Sex With Stroke and Bleeding Risk of Apixaban and Rivaroxaban in Elderly Atrial Fibrillation Patients Using Propensity Score Weights
por: Gulilat, Markus, et al.
Publicado: (2021)

Correction to: Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis
por: Sakuma, Ichiro, et al.
Publicado: (2019)

Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy
por: Wells, Philip S, et al.
Publicado: (2014)

Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gaeu4rh471qbpgt56ifgtdohdk